Madrigal Pharmaceuticals

Breakthrough Liver Drug Shows Powerful Two-Year Gains — But Raises a Critical Warning

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) unveiled new two-year data showing that its flagship therapy Rezdiffra produced sustained improvements in patients with compensated MASH cirrhosis, a population with …

Breakthrough Liver Drug Shows Powerful Two-Year Gains — But Raises a Critical Warning Read More